Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Am J Ophthalmol. 2021 May 11;228:142–151. doi: 10.1016/j.ajo.2021.03.040

Classification criteria for tubercular uveitis

The Standardization of Uveitis Nomenclature (SUN) Working Group*
PMCID: PMC8634785  NIHMSID: NIHMS1692708  PMID: 33845014

Abstract

Purpose:

To determine classification criteria for tubercular uveitis

Design:

Machine learning of cases with tubercular uveitis and 14 other uveitides.

Methods:

Cases of non-infectious posterior or panuveitis, and of infectious posterior or panuveitis were collected in an informatics-designed preliminary database, and a final database was constructed of cases achieving supermajority agreement on the diagnosis, using formal consensus techniques. Cases were analyzed by anatomic class, and each class was split into a training set and a validation set. Machine learning using multinomial logistic regression was used on the training set to determine a parsimonious set of criteria that minimized the misclassification rate among the intermediate uveitides. The resulting criteria were evaluated on the validation sets.

Results:

Two hundred seventy-seven cases of tubercular uveitis were evaluated by machine learning against other uveitides. Key criteria for tubercular uveitis were a compatible uveitic syndrome, including: 1) anterior uveitis with iris nodules, 2) serpiginous-like tubercular choroiditis, 3) choroidal nodule (tuberculoma), 4) occlusive retinal vasculitis, and 5) in hosts with evidence of active systemic tuberculosis, multifocal choroiditis; and evidence of tuberculosis, including: 1) histologically- or microbiologically-confirmed infection, 2) positive interferon-γ release assay test, or 3) positive tuberculin skin test. The overall accuracy of the diagnosis of tubercular uveitis versus other uveitides in the validation set was 98.2% (95% CI 96.5, 99.1). The misclassification rates for tubercular uveitis were: training set 3.4%; and validation set 3.6%.

Conclusions:

The criteria for tubercular uveitis had a low misclassification rate and appeared to perform sufficiently well for use in clinical and translational research.

PRECIS

Using a formalized approach to developing classification criteria, including informatics-based case collection, consensus-technique-based case selection, and machine learning, classification criteria for tubercular uveitis were developed. Key criteria included a one of five compatible uveitic syndromes and evidence of active systemic tuberculosis, positive IGRA assay, or positive tuberculin skin test. The resulting classification criteria had a low misclassification rate.


Globally, disease caused by Mycobacterium tuberculosis is one of the 10 leading causes of death. It is estimated that 10 million persons globally developed tuberculosis (TB) in 2017, and that 1.6 million persons died from TB. Although TB is worldwide in its distribution, in 2017 two-thirds of cases occurred in just eight countries (India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa), and 87% of cases occurred in the World Health Organization’s list of 30 high TB burden countries. Nine percent of cases of TB disease are co-infected with the Human Immunodeficiency Virus (HIV), of which 72% occurred in Africa. Only 6% of cases occurred in the WHO European region and 3% in the WHO region of the Americas.1 In the United States in 2017, there were 9,093 cases reported, 70% of which occurred in individuals born outside the United States.2 Although 10 million persons developed tubercular disease (active TB) globally in 2017, latent TB is estimated to affect 1.7 billion people, about 23% of the world’s population; these individuals are at risk for developing active TB.1

Several ocular uveitic presentations have been attributed to ocular TB. These include: 1) anterior uveitis with iris nodules; 2) serpiginous-like tubercular choroiditis; 3) choroidal granuloma (i.e. tuberculoma); 4) occlusive retinal vasculitis; and 5) in immune compromised persons, multifocal choroiditis in the context of active systemic TB.38 Complicating the diagnosis of ocular TB is the fact that a minority of persons with ocular TB have evident active systemic TB, and that approximately one-half or less have evidence of current or previous pulmonary infection on chest imaging.37 As such, diagnosis of ocular TB usually employs evidence of TB infection with a tuberculin skin test (TST) or an interferon-γ release assay (IGRA), neither of which distinguishes between latent and active TB.9,10 There are no randomized clinical trials demonstrating a response to anti-tubercular therapy, but there are several large case series.37,11,12 However, evaluation of treatment studies often has been confounded by the concomitant use of corticosteroids and anti-tubercular therapy.6,7,11 Nevertheless, most patients with the syndromes listed above appear to respond to antitubercular therapy,47,11,12 and at least one study demonstrated a superior outcome among patients presumed to have ocular TB treated with anti-tubercular therapy compared to those not treated with anti-tubercular therapy.12 Treatment regimens recommended for ocular TB typically presume underlying active TB and treat as such (e.g. 4 drugs for 2 months, followed by 2 drugs for an additional 4–10 months).4 Nevertheless, there is a lack of consensus on the diagnosis and treatment of tubercular uveitis.13

The Standardization of Uveitis Nomenclature (SUN) Working Group is an international collaboration, which has developed classification criteria for the leading 25 uveitides using a formal approach to development and classification.1420 Among the uveitides studied was tubercular uveitis.

Methods

The SUN Developing Classification Criteria for the Uveitides project proceeded in four phases as previously described: 1) informatics, 2) case collection, 3) case selection, and 4) machine learning.16,18,20

Informatics.

As previously described, the consensus-based informatics phase permitted the development of a standardized vocabulary and the development of a standardized, menu-driven hierarchical case collection instrument.16

Case collection and case selection.

De-identified information was entered into the SUN preliminary database by the 76 contributing investigators for each disease as previously described.16,18,20 Cases in the preliminary database were reviewed by committees of 9 investigators for selection into the final database, using formal consensus techniques described in the accompanying article.18,20 Because the goal was to develop classification criteria,19 only cases with a supermajority agreement (>75%) that the case was the disease in question were retained in the final database (i.e. were “selected”).18,20

Machine learning.

The final database was analyzed by anatomic class, and each class was randomly separated into a learning set (~85% of the cases) and a validation set (~15% of the cases) for each disease as described in the accompanying article.20 Machine learning was used on the learning sets to determine criteria that minimized misclassification. The criteria then were tested on the validation sets; for both the learning set and the validation set, the misclassification rate was calculated for each disease. The misclassification rate was the proportion of cases classified incorrectly by the machine learning algorithm when compared to the consensus diagnosis. For tubercular uveitis the diseases against which it was evaluated in the machine learning phase included infectious posterior and panuveitides (acute retinal necrosis, cytomegalovirus retinitis, syphilitic uveitis, and toxoplasmic retinitis), non-infectious posterior uveitides (acute posterior multifocal placoid pigment epitheliopathy, birdshot chorioretinitis, multiple evanescent white dot syndrome, multifocal choroiditis with panuveitis, punctate inner choroiditis, serpiginous choroiditis) and non-infectious panuveitides, (Behçet disease, sarcoidosis-associated uveitis, sympathetic ophthalmia, Vogt-Koyanagi-Harada disease) respectively. No cases of tubercular anterior uveitis were collected.

The study adhered to the principles of the Declaration of Helsinki. Institutional Review Boards (IRBs) at each participating center reviewed and approved the study; the study typically was considered either minimal risk or exempt by the individual IRBs.

Comparison of cases with evidence of systemic tuberculosis versus those without and comparison of cases from high-TB-burden countries vs those not from high-TB-burden countries.

Cases with evidence of TB in an extraocular organ were compared to those with ocular disease alone and a positive TST or IGRA, and cases from high-TB-burden countries were compared to those not from high-TB-burden countries. For categorical variables, comparison was performed with the chi-square test or the Fisher’s exact test when the count of a variable was less than 5. Continuous variables were summarized as medians and compared with the Wilcoxon rank sum test. For characteristics with multiple categorical grades, values above and below the median were compared. P-values are nominal and two-sided.

Results

Three hundred fifty-eight cases of tubercular uveitis were collected, and 277 (77%) achieved supermajority agreement on the diagnosis during the “selection” phase and were used in the machine learning phase. Cases of tubercular uveitis were evaluated in the machine learning for infectious posterior and panuveitides, non-infectious posterior uveitides, and non-infectious panuveitides. The details of the machine learning results for these diseases are outlined in the accompanying article.20 The characteristics of cases with tubercular uveitis are listed in Table 1. Four patterns of cases emerged: 1) serpiginous-like tubercular choroiditis; 2) choroidal nodule (tuberculoma); 3) occlusive retinal vasculitis; and 4) in a small proportion of cases, all with systemic, extraocular tuberculosis, multifocal choroiditis. A small number of cases had both retinal vasculitis and multifocal choroiditis. A comparison of cases with evidence of systemic TB and those without (i.e. with only a positive TST or IGRA for TB) is shown as Table 2. Cases with evidence of systemic TB were less likely to be of Asian origin, more likely to have vitreous inflammation, and less likely to have serpiginous-like tubercular choroiditis. A comparison of cases from high-TB-burden countries and those not from high-TB-burden countries is shown as Table 3. Cases from high-TB-burden countries had a greater proportion of cases with serpiginous-like-choroiditis, whereas those from “low-TB-burden” countries had a greater proportion of cases with retinal vasculitis and had a greater proportion of cases with higher grades of anterior chamber and vitreous inflammation. The criteria developed after machine learning are listed in Table 4. The key features of the criteria are a compatible ocular uveitic syndrome and evidence of infection with TB. Compatible uveitic syndromes included anterior uveitis with iris nodules, serpiginous-like tubercular choroiditis (Figure 1), a choroidal nodule (“tuberculoma”, Figure 2), and occlusive retinal vasculitis (Figure 3). The overall accuracies by anatomic class were: infectious posterior and panuveitides, learning set 92.1% and validation set 93.3% (95% confidence interval [CI] 88.1, 96.3); non-infectious posterior uveitides, learning set 93.9% and validation set 98.0% (95% CI 94.3, 99.3); and non-infectious panuveitides, learning set 96.3% and validation set 94.0% (95% CI 89.0, 96.8).16 The overall accuracy of the diagnosis of tubercular uveitis versus other uveitides in the validation set was 98.2% (95% CI 96.5, 99.1). The misclassification rates for tubercular uveitis in the learning set were as follows: against non-infectious posterior uveitides 7.5%, against non-infectious panuveitides 5.3%, and against infectious posterior and panuveitides 1.3%. Overall the misclassification rate for tubercular uveitis in the learning set was 3.4%, In the validation set the misclassification rates were as follows: against non-infectious posterior uveitides 0%, against non-infectious panuveitides 6.7%, and against infectious posterior and panuveitides 5.0%. Overall, the misclassification rate for tubercular uveitis in the validation set was 3.6%.

Table 1.

Characteristics of Cases with Tubercular Uveitis

Characteristic Result
Number cases 277
Demographics
Age, median, years (25th 75th percentile) 32 (25, 44)
Gender (%)
 Men 72
 Women 28
Race/ethnicity (%)
 White, non-Hispanic 9
 Black, non-Hispanic 4
 Hispanic 1
 Asian, Pacific Islander 80
 Missing 6
Uveitis History
Uveitis course (%)
 Acute, monophasic 25
 Acute, recurrent 3
 Chronic 66
 Indeterminate 6
Laterality (%)
 Unilateral 44
 Unilateral, alternating 0
 Bilateral 56
Ophthalmic examination
Keratic precipitates (%)
 None 88
 Fine 5
 Round 3
 Stellate 0
 Mutton Fat 4
Anterior chamber cells (%)
 Grade 0 70
 ½+ 10
 1+ 6
 2+ 10
 3+ 3
 4+ 1
Anterior chamber flare (%)
 Grade 0 86
 1+ 10
 2+ 3
 3+ 1
 4+ 0
Iris (%)
 Normal 93
 Posterior synechiae 6
 Iris nodules 1
 Iris atrophy (sectoral, patchy, or diffuse) 0
 Heterochromia 0
Intraocular pressure (IOP), involved eyes
 Median, mm Hg (25th, 75th percentile) 15 (14, 18)
 Proportion patients with IOP>24 mm Hg either eye (%) 5
Vitreous cells (%)
 Grade 0 34
 ½+ 16
 1+ 27
 2+ 19
 3+ 4
 4+ 0
Vitreous haze (%)
 Grade 0 65
 ½+ 13
 1+ 12
 2+ 6
 3+ 4
 4+ 0
Vitreous snowballs (%) 11
Pars plana snowbanks (%) 1
Serpiginous-like tubercular choroiditis (%) 43
Choroidal nodule (i.e. tuberculoma) (%) 4
Retinal vasculitis (%)* 53
Multifocal choroiditis (%)* 6
Systemic disease
Bilateral hilar adenopathy 6
Immunocompromised patients (%) 2
Evidence of infection with M. tuberculosis (%) 100
Histologic or culture confirmation of infection in another organ 17
Positive interferon- γ release assay (IGRA) 29
Positive tuberculin skin test (e.g. PPD) 88
*

9 cases categorized as primarily retinal vasculitis also had a multifocal choroiditis, and 8 cases had a multifocal choroiditis accompanying systemic tuberculosis.

All cases had at least one positive test. 242 of 259 (93%) cases tested with a tuberculin skin test were positive, and 79 of 79 (100%) cases tested with an IGRA were positive.

Table 2.

Characteristics of Cases with Evidence of Systemic Tuberculosis vs those Without

Characteristic Evidence Systemic TB* Positive TST or IGRA only* P-value
Number cases 48 229
Demographics
Age, median, years (25th 75th percentile) 32 (23, 48) 32 (25, 44) 0.69
Gender (%) 0.60
 Men 69 73
 Women 31 27
Race/ethnicity (%) 0.003
 Asian 62 84
 Non-Asian 38 16
Uveitis History
Uveitis course (%) 0.08
 Acute, monophasic 23 24
 Acute, recurrent 0 3
 Chronic 62 67
 Indeterminate 14 4
Laterality (%) 0.57
 Unilateral 38 46
 Bilateral 62 54
Ophthalmic examination
Keratic precipitates (%) 0.07
 None 80 90
 Fine 12 4
 Round 4 3
 Mutton Fat 4 3
Anterior chamber cells (%) 0.83
 Grade 0 58 72
 ≥Grade ½+ 42 38
Anterior chamber flare (%) 0.13
 Grade 0 77 88
 ≥grade 1+ 23 12
Iris (%) 0.89
 Normal 92 88
 Posterior synechiae 8 9
 Iris nodules 0 3
Intraocular pressure (IOP), involved eyes
 Median, mm Hg (25th, 75th percentile) 14 (12, 17) 16 (14, 18) 0.15
 Percent cases with IOP>24 mm Hg either eye 4 5 0.84
Vitreous cells (%) 0.62
 Grade 0 or ½+ 50 50
 ≥grade 1+ 50 50
Vitreous haze (%) 0.02
 Grade 0 50 68
 ≥grade ½+ 50 32
Serpiginous-like tubercular choroiditis (%) 17 49 <0.001
Choroidal nodule (i.e. tuberculoma) (%) 10 3 0.03
Retinal vasculitis (%) 60 52 0.29
*

TB = tuberculosis. Systemic TB = evidence of infection in an extraocular organ. TST = tuberculin skin test (e.g. PPD). IGRA = interferon-γ release assay for TB (e.g. Quantiferon-gold or T-spot).

Table 3.

Characteristics of Cases by Case Source (High-tuberculosis-burden Country vs Low-tuberculosis burden Country)

Country Type for Case Source*
Characteristic High-TB-burden Low-TB-burden P-value
Number cases 188 89
Demographics
Age, median, years (25th, 75th percentile) 30 (23, 40) 41 (29, 57) <0.001
Gender (%) 0.07
 Men 76 65
 Women 24 35
Uveitis History
Uveitis course (%) <0.001
 Acute, monophasic 34 8
 Acute, recurrent 2 2
 Chronic 64 73
 Indeterminate 0 17
Laterality (%) 0.01
 Unilateral 49 33
 Bilateral 51 67
Ophthalmic examination
Keratic precipitates (%) <0.001
 None 95 71
 Fine or round 3 19
 Mutton fat 2 10
Anterior chamber cells (%) <0.001
 Grade 0 79 50
 ≥ grade ½+ 21 50
Anterior chamber flare (%) 0.01
 Grade 0 90 78
 ≥ grade 1+ 10 22
Iris (%) <0.001
 Normal 97 85
 Posterior synechiae 2 15
 Iris nodules 1 0
Intraocular pressure (IOP) involved eyes
 Median, mm Hg (25th, 75th percentile) 15 (14, 17) 16 (12, 18) 0.91
 Cases with IOP >24 mm Hg either eye (%) 2 11 0.002
Vitreous cells (%) 0.12
 ≤grade ½+ 52 46
 ≥grade 1+ 48 54
Vitreous haze (%) <0.001
 Grade 0 73 46
 ≥grade ½+ 27 54
Serpiginous-like tubercular choroiditis (%) 54 21 <0.001
Choroidal nodule (i.e. tuberculoma) (%) 4 3 0.51
Retinal vasculitis (%) 46 68 0.001
*

TB = tuberculosis. High-burden defined by World Health Organization.

Table 4.

Classification Criteria for Tubercular Uveitis

Criteria
1. Evidence of a tubercular uveitis compatible uveitic syndrome
 a. anterior uveitis with iris nodules
 b. serpiginous-like tubercular choroiditis
 c. choroidal nodule (i.e. tuberculoma)
 d. in individuals with active systemic tuberculosis, multifocal choroiditis
 e. occlusive retinal vasculitis
AND
2. Evidence of infection with Mycobacterium tuberculosis, either
 a. histologically- or microbiologically-confirmed infection with M. tuberculosis* OR
 b. positive interferon-γ release assay (IGRA) OR
 c. positive tuberculin skin test
Exclusions
1. Positive serology for syphilis using a treponemal test
2. Positive biopsy for sarcoidosis (and therefore an absence of histological or microbiologic confirmation of infection with M. tuberculosis)
3. Uveitic syndrome compatible with either sarcoidosis-associated uveitis or tubercular uveitis and bilateral hilar adenopathy on chest imaging without histological or microbiologic confirmation of the diagnosis of infection with M. tuberculosis §
*

E.g. biopsy, fluorochrome stain, culture, or polymerase chain reaction based assay.

E.g. Quantiferon-gold or T-spot.

E.g. Purified protein derivative (PPD) skin test; a positive result should be >10 mm induration. However, a positive skin test and a negative IGRA should be taken as evidence of atypical mycobacterial infection and not tuberculosis.

§

In patients with a uveitic syndrome compatible either with sarcoidosis-associated uveitis or with tubercular uveitis, bilateral hilar adenopathy, and evidence of latent tuberculosis (e.g. positive tuberculin skin test or IGRA), the classification requires histological or microbiologic confirmation of the diagnosis (i.e. classification cannot be made without such confirmation).

Figure 1.

Figure 1.

Fluorescein angiogram of serpiginous-like tubercular choroiditis, demonstrating the late staining of the borders of several of the multifocal choroidal lesions.

Figure 2.

Figure 2.

Fundus photograph of a choroidal tuberculoma with overlying serous fluid.

Figure 3.

Figure 3.

Fundus photograph of retinal vasculitis due to tuberculosis, demonstrating intraretinal hemorrhage and vascular sheathing.

Data on testing for TB was available on 1397 cases in the SUN database, of whom 277 had tubercular uveitis and 1120 did not. A TST was positive in 111 (12%) of 917 cases without tubercular uveitis and a documented TST result, and an IGRA was positive in 23 (9%) of 252 cases without tubercular uveitis and a documented IGRA result. None of these TB-test-positive not-tubercular-uveitis cases had a TB-compatible uveitic syndrome, and all had well-defined alternative uveitic diagnoses.

Discussion

The classification criteria developed by the SUN Working Group for tubercular uveitis have a low misclassification rate, indicating good discriminatory performance against other uveitides. Because of the high prevalence of latent TB and the fact that less than 1% of individuals with latent TB will have active TB, not all cases of uveitis with a positive tuberculin skin test or a positive IGRA assay will have uveitis due to tuberculosis. In fact, it has been estimated that the positive predictive values for a positive tuberculin skin test and a positive IGRA for ocular tuberculosis in the United States are 1% and 11%, respectively.9,10 As such a compatible uveitic syndrome (one typically associated with tuberculosis) is required for diagnosis in the classification criteria. Due to the selective nature of the SUN case collection, great care should be taken in extrapolating the SUN TB test data, as the database was enriched for TB compared to what is seen in clinical care in the United States and other low-TB-burden countries. Nevertheless, if the calculated sensitivity and specificity of the SUN data were to be applied to a United States (or other low-TB-burden country) population, the positive predictive value of a positive PPD would be <1% and of a positive IGRA would be 30%, results qualitatively similar to the published data, and again emphasizing the need for a TB-compatible uveitic syndrome in the criteria.

The potential for a false positive TST among patients with a history of bacille Calmette-Guérin (BCG) vaccination for TB has been an item of concern among ophthalmologists. However, it appears that for individuals receiving BCG vaccination as an infant, by 10 years after vaccination, the TST will be negative in ~99% of persons (i.e. estimated false positive rate ~1%),21 and the TST (positive result >10 mm) can be used reliably to diagnose TB in adults even with a history of BCG vaccination as an infant. Although the false positive rate may be higher if vaccination is given after infancy, the absolute prevalence of false positive tuberculin skin tests due to BCG vaccination has been estimated at <1% to 2.3%.21

Polymerase chain reaction (PCR) is a sensitive technique for identifying pathogens in small volume samples, such as from the eye, and is used routinely to diagnose viral intraocular infections (e.g. CMV, herpes simplex virus, varicella zoster virus) and ocular toxoplasmosis.20 Small case series have suggested promise for mycobacterial PCR analysis of aqueous specimens obtained by paracentesis.2224 Reported sensitivity has ranged from ~55% to 75%, and specificity as high as 100%.2224 However, negative results in patients with active systemic TB and uveitis24 and discordant results between assays (using different primers and amplification conditions) as high as 30%, have limited its widespread adoption.23 In its analysis of PCR for ocular TB, the Collaborative Ocular Tuberculosis Study concluded that “… PCR is not commonly done for diagnosing intraocular TB and … may not influence management ….”24 Furthermore, no studies have compared the performance of PCR for different presentations of tubercular uveitis (e.g. serpiginous-like tubercular choroiditis vs. choroidal tuberculoma vs. panuveitis with occlusive retinal vasculitis), where mycobacterial load in the aqueous and/or vitreous might be expected to vary. We had few data on the use of PCR for ocular TB and could not evaluate its performance. Given the utility of PCR for other pathogens,20 it might be reasonable to diagnose ocular TB with a positive PCR assay from intraocular fluids, but the relatively low sensitivity suggests that it cannot be used to exclude ocular TB at this time. Moreover, the limited amount of data, the discordance between assays, and the lack of widespread use resulted in its not being included in the criteria at this time. As assays are developed further, standardized, performance improved, and appropriate clinical studies performed, one might expect a positive PCR for TB from an intraocular fluid specimen to be added to the SUN Classification Criteria in the future.

Less than one-half of individuals with ocular TB have evidence of systemic disease,4,5 a result also seen with our data. We compared those with evidence of extra-ocular TB to those without. Those without evidence of extra-ocular TB were more likely to be Asian and have serpiginous-like tubercular choroiditis, although serpiginous-like tubercular choroiditis was seen among those with evidence of systemic TB. Whether this difference represents ascertainment bias, regional diagnostic bias, regional variation in the presentation of ocular TB, chance variation and/or other, unidentified factors is unknown. However, the successful treatment of serpiginous-like tubercular choroiditis with anti-tubercular therapy has been reported several times, suggesting that it is due to M. tuberculosis infection.4,6,11,12 Although there were differences in the distributions of the disease presentations between cases with systemic, extraocular TB and those without, a similar set of presentations of disease were present, suggesting that these patterns of disease are related to TB. Similarly cases from high-TB-burden countries and those from low-TB-burden countries had different distributions of disease presentations, but the same set of disease presentations, suggesting generalizability of these criteria.

The presence of any of the exclusions in Table 4 suggests an alternate diagnosis, and the diagnosis of tubercular uveitis should not be made in their presence. In prospective studies many of these tests will be performed routinely, and the alternative diagnoses excluded. However, in retrospective studies based on clinical care, not all of these tests may have been performed. Hence the presence of an exclusionary criterion excludes tubercular uveitis, but the absence of such testing does not always exclude the diagnosis of tubercular uveitis if the criteria for the diagnosis are met. However, there are several tubercular uveitis compatible ocular syndromes that also are compatible with sarcoidosis-associated uveitis, including chronic anterior uveitis with iris nodules, a choroidal nodule, and panuveitis with retinal vascular sheathing/occlusion. In TB-non-endemic areas these ocular findings and bilateral hilar adenopathy on chest imaging nearly always are sarcoidosis.25 However, in TB-endemic areas, bilateral hilar adenopathy may be due to TB, and patients with evidence of latent TB (e.g. positive TST or IGRA), bilateral hilar adenopathy and uveitis could have either disease.25 In these situations, the only way to confirm the diagnosis is biopsy. In the SUN database 6.1% of cases of TB uveitis had bilateral hilar adenopathy on chest imaging, of whom 76% were Asian (and therefore presumably from a TB-endemic country). A study of patients with uveitis and a positive IGRA in a non-endemic country suggested that when a biopsy (or bronchoalveolar lavage) is performed ~75% of these patients will have sarcoidosis and not TB.5 Nevertheless, 36% of the patients with uveitis and bilateral hilar adenopathy in this study did not undergo additional testing and were presumed to have ocular TB. As such, patients with a uveitis compatible either with sarcoidosis or with tubercular uveitis, bilateral hilar adenopathy, and a positive tuberculin skin test or IGRA cannot be reliably diagnosed as sarcoidosis or tuberculosis without biopsy or microbiologic confirmation of the diagnosis.

Classification criteria are employed to diagnose individual diseases for research purposes.19 Classification criteria differ from clinical diagnostic criteria, in that although both seek to minimize misclassification, when a trade-off is needed, diagnostic criteria typically emphasize sensitivity, whereas classification criteria emphasize specificity,19 in order to define a homogeneous group of patients for inclusion in research studies and limit the inclusion of patients without the disease in question that might confound the data. The machine learning process employed did not explicitly use sensitivity and specificity; instead it minimized the misclassification rate. Because we were developing classification criteria and because the typical agreement between two uveitis experts on diagnosis is moderate at best,18 the selection of cases for the final database (“case selection”) included only cases which achieved supermajority agreement on the diagnosis. As such, some cases which clinicians would diagnose with tubercular uveitis may not be so classified by classification criteria.

One excluded disease was intermediate uveitis with evidence of latent TB. There was no consensus as to whether this represents an “ocular TB compatible syndrome”. Studies of anti-tubercular therapy for presumed ocular TB have reported disappointing results for intermediate uveitis, with substantially greater failure rates than for other syndromes,11 suggesting that many if not most such cases represent uveitis with unrelated latent TB rather than ocular TB. Demonstration of a distinct morphologic syndrome or development of a widely-used reliable PCR assay for intraocular TB that could diagnose tubercular intermediate uveitis could lead to the inclusion of intermediate uveitis in the criteria. We had no cases of chronic anterior uveitis with iris nodules in the SUN data base, and could not evaluate it. However, anterior uveitis with iris nodules is a well described manifestation of tubercular uveitis,5 and it was included as a tubercular uveitis compatible presentation in the criteria.

The Collaborative Ocular Tuberculosis Study (COTS) has used a Delphi approach to derive consensus guidelines for the management of ocular TB.7,11,24 These guidelines differ from the SUN classification criteria, which are targeted for clinical research and may be, of necessity, more restrictive than COTS guidelines for clinical care. Nevertheless, they appear to contain overlapping elements, including recognition of several of the major TB uveitis presentations.

In conclusion, the criteria for tubercular uveitis outlined in Table 4 appear to perform sufficiently well for use as classification criteria in clinical research.20

Acknowledgments

Grant support: Supported by grant R01 EY026593 from the National Eye Institute, the National Institutes of Health, Bethesda, MD, USA; the David Brown Fund, New York, NY, USA; the Jillian M. And Lawrence A. Neubauer Foundation, New York, NY, USA; and the New York Eye and Ear Foundation, New York, NY, USA.

Footnotes

1

Writing committee: Douglas A. Jabs, MD, MBA2,3; Rubens Belfort, Jr., MD, PhD, MBA4; Bahram Bodaghi, PhD, FEBOph5; Elizabeth Graham, FRCP, DO, FRCOphth6; Vishali Gupta, MD7; Gary N, Holland, MD8; Susan L. Lightman, PhD, FRCP, FRCOphth9,10; Neal Oden, PhD11; Alan G. Palestine, MD12; Justine R. Smith, FRANZCO, PhD13; Jennifer E. Thorne, MD, PhD2,3; Brett E. Trusko, PhD, MBA14

2

Affiliations: 1Members of the SUN Working Group are listed online at ajo.com. From 2the Department of Epidemiology, the Johns Hopkins University Bloomberg School of Public Health, and 3the Wilmer Eye Institute, the Department of Ophthalmology, the Johns Hopkins University School of Medicine, Baltimore, MD, USA; 4the Department of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil; 5the Department of Ophthalmology, Pitie-Salpetriere Hospital, IHU FOReSIGHT, Sorbonne University, Paris, France; 6St. Thomas Hospital Medical Eye Unit, London, UK; 7the Advanced Eye Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India; 8UCLA Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; 9Moorfields Eye Hospital, London, UK; 10Institute of Ophthalmology, University College London, London, UK; 11the Emmes Company, LLC, Rockville, MD, USA; 12the Department of Ophthalmology, University of Colorado School of Medicine, Aurora, Co, USA; 13the Flinders University College of Medicine and Public Health, Adelaide, Australia; 14the Department of Medicine, Texas A&M University, College Station, TX, USA

3

Conflict of Interest: Douglas A. Jabs: none; Rubens Belfort, Jr.: none; Bahram Bodaghi: none; Elizabeth Graham: none; Vishali Gupta: none; Gary Holland: none; Susan L. Lightman: none; Neal Oden: none; Alan G. Palestine: none; Justine R. Smith: none; Jennifer E. Thorne: Dr. Thorne engaged in a portion of this research as a consultant and was compensated for the consulting service; Brett E. Trusko: none.

Publisher's Disclaimer: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

REFERENCES

  • 1.World Health Organization. Global Tuberculosis Report 2018. Accessed 9 April 2019 at who.int/global tuberculosis report 2018.
  • 2.Stewart RJ, Tsang CA, Pratt RH, Price SF, Langer AJ. Tuberculosis – United States, 2017. Morbidity Mortal Weekly Report 2018;67:317–23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Bansal R, Gupta A, Gupta V, Dogra MR, Sharma A, Bambery P. Tubercular serpiginous-like choroiditis presenting as multifocal serpiginoid choroiditis. Ophthalmology 2012;119:2334–42. [DOI] [PubMed] [Google Scholar]
  • 4.Patel SS, Saraiya NV, Tessler HH, Goldstein DA. Mycobacterial ocular inflammation: delay in diagnosis and other factors impacting morbidity. JAMA Ophthalmol 2013;131:752–8. [DOI] [PubMed] [Google Scholar]
  • 5.La Distia NR, van Velthoven ME, Ten Dam-vanLoon NH, et al. Clinical manifestations of patients with intraocular inflammation and positive Quantiferon-TB gold in-tube test in a country nonendemic for tuberculosis. Am J Ophthalmol 2014;137:754. [DOI] [PubMed] [Google Scholar]
  • 6.Agrawal R, Gunasekeran DV, Agarwal A, et al. The Collaborative Ocular Tuberculosis Study (COTS)-1: a multinational description of the spectrum of choroidal involvement in 245 patients with tubercular uveitis. Ocul Immunol Inflamm 2018;ePub ahead of print. [DOI] [PubMed] [Google Scholar]
  • 7.Gunasekeran DV, Agrawal R, Agarwal A, et al. The Collaborative Ocular Tuberculosis Study (COTS)-1: a multinational review of 251 patients with tubercular retinal vasculitis. Retina 2019;39:1623–30. [DOI] [PubMed] [Google Scholar]
  • 8.Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc 1995;623–83. [PMC free article] [PubMed] [Google Scholar]
  • 9.Rosenbaum JT, Wernick R. The utility of routine screening of patients with uveitis for systemic lupus erythematosus or tuberculosis. A Bayesian analysis. Arch Ophthalmol 1990;108:1291–3. [DOI] [PubMed] [Google Scholar]
  • 10.Albini TA, Karakousis PC, Rao NA. Interferon-gamma release assays in the diagnosis of tubercular uveitis. Am J Ophthalmol 2008;146:486–8. [DOI] [PubMed] [Google Scholar]
  • 11.Agrawal R, Gunasekeran DV, Grant R, et al. Clinical features and outcomes of patients with tubercular uveitis treated with antitubercular therapy in the Collaborative Ocular Tuberculosis Study (COTS)-1. JAMA Ophthamol 2017;135:1318–27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Tomkins-Netzer O, Leong BCS, Zhang X, Lightman S, McCluskey PJ, Sydney-London Ocular Latent TB Study Group. Effect of antitubercular therapy on uveitis associated with latent tuberculosis. Am J Ophthalmol 2018;190:164–70. [DOI] [PubMed] [Google Scholar]
  • 13.Lou SM, Larkin KL, Winthrop K, Rosenbaum JT, Uveitis Specialists Study Group. Lack of consensus in the diagnosis and treatment for ocular tuberculosis among uveitis specialists. Ocular Immunol Inflamm 2015;23:25–31. [DOI] [PubMed] [Google Scholar]
  • 14.Jabs DA, Rosenbaum JT, Nussenblatt RB, the Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Report of the first international workshop. Am J Ophthalmol 2005;140:509–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Jabs DA, Busingye J. Approach to the diagnosis of the uveitides. Am J Ophthalmol 2013;156:228–36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Trusko B, Thorne J, Jabs D, et al. Standardization of Uveitis Nomenclature Working Group. The SUN Project. Development of a clinical evidence base utilizing informatics tools and techniques. Methods Inf Med 2013;52:259–65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Okada AA, Jabs DA. The SUN Project. The future is here. Arch Ophthalmol 2013;131:787–9. [DOI] [PubMed] [Google Scholar]
  • 18.Jabs DA, Dick A, Doucette JT, Gupta A, Lightman S, McCluskey P, Okada AA, Palestine AG, Rosenbaum JT, Saleem SM, Thorne J, Trusko, B for the Standardization of Uveitis Nomenclature Working Group. Interobserver agreement among uveitis experts on uveitic diagnoses: the Standard of Uveitis Nomenclature experience. Am J Ophthalmol 2018; 186:19–24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Aggarwal R, Ringold S, Khanna D, et al. Distinctions between diagnostic and classification criteria. Arthritis Care Res 2015;67:891–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.The Standardization of Uveitis Nomenclature (SUN) Working Group. Development of classification criteria for the uveitides. Am J Ophthalmol 2020;volume:pp. [DOI] [PubMed] [Google Scholar]
  • 21.Farhat M, Greenway C, Pal M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tubercular mycobacteria? Int J Tuberc Lung Dis 2006;10:1192–1204. [PubMed] [Google Scholar]
  • 22.Sharma K, Gupta V, Bansal R, Sharma A, Sharma M, Gupta A. Novel multi -targeted polymerase chain reaction for diagnosis of presumed tubercular uveitis. J Ophthalmic Inflamm Infect 2013;28:25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Kataria P, Kumar A, Bansal R, et al. devPCR for the diagnosis of intraocular tuberculosis. Ocular Immunol Inflamm 2015;23:47–52. [DOI] [PubMed] [Google Scholar]
  • 24.Agrawal A, Agrawal R, Gunasekaran DV, et al. The Collaborative Ocular Tuberculosis Study (COTS)-1 report 3: polymerase chain reaction in the diagnosis and management of tubercular uveitis: global trends. Ocular Immunol Inflamm 2019;27:466–73. [DOI] [PubMed] [Google Scholar]
  • 25.The Standardization of Uveitis Nomenclature (SUN) Working Group. Classification criteria for sarcoidosis-associated uveitis. Am J Ophthalmol 2020;volume:pp. [DOI] [PubMed] [Google Scholar]

RESOURCES